Clinical and microbiological characteristics of bloodstream infections among patients with haematological malignancies with and without neutropenia at a medical centre in northern Taiwan, 2008-2013.

[1]  C. H. Camargo,et al.  Bloodstream infection caused by extensively drug-resistant Acinetobacter baumannii in cancer patients: high mortality associated with delayed treatment rather than with the degree of neutropenia. , 2016, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[2]  M. Mikulska,et al.  Bloodstream infections in neutropenic cancer patients: A practical update , 2016, Virulence.

[3]  P. Ljungman,et al.  The challenge of antibiotic resistance in haematology patients , 2016, British journal of haematology.

[4]  C. Crank,et al.  Vancomycin-resistant enterococcal infections: epidemiology, clinical manifestations, and optimal management , 2015, Infection and Drug Resistance.

[5]  E. Anaissie,et al.  Tackling antibiotic resistance in febrile neutropenia: current challenges with and recommendations for managing infections with resistant Gram-negative organisms , 2015, Expert review of hematology.

[6]  H. Rohde,et al.  A multicentre cohort study on colonization and infection with ESBL-producing Enterobacteriaceae in high-risk patients with haematological malignancies. , 2014, The Journal of antimicrobial chemotherapy.

[7]  P. Gastmeier,et al.  Infection control issues in patients with haematological malignancies in the era of multidrug-resistant bacteria. , 2014, The Lancet. Oncology.

[8]  R. Bonomo,et al.  Antibiotic-resistant gram-negative bacterial infections in patients with cancer. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  V. Fowler,et al.  Invasive gram-positive bacterial infection in cancer patients. , 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  E. Trecarichi,et al.  Antimicrobial-resistant Gram-negative bacteria in febrile neutropenic patients with cancer: current epidemiology and clinical impact , 2014, Current opinion in infectious diseases.

[11]  L. Biehl,et al.  Colonization and infection with extended spectrum beta-lactamase producing Enterobacteriaceae in high-risk patients – Review of the literature from a clinical perspective , 2014, Critical reviews in microbiology.

[12]  K. Rolston,et al.  The current spectrum of infection in cancer patients with chemotherapy related neutropenia , 2014, Infection.

[13]  J. Gea-Banacloche.  Evidence-based approach to treatment of febrile neutropenia in hematologic malignancies. , 2013, Hematology. American Society of Hematology. Education Program.

[14]  Ronald N. Jones,et al.  Tigecycline activity tested against antimicrobial resistant surveillance subsets of clinical bacteria collected worldwide (2011). , 2013, Diagnostic microbiology and infectious disease.

[15]  J. Karlowsky,et al.  Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study. , 2013, The Journal of antimicrobial chemotherapy.

[16]  Yee-Chun Chen,et al.  Microbiological and clinical characteristics of vancomycin-resistant Enterococcus faecium bacteraemia in Taiwan: implication of sequence type for prognosis. , 2012, The Journal of antimicrobial chemotherapy.

[17]  Yoon-Seon Lee,et al.  Predictive factors for poor prognosis febrile neutropenia , 2012, Current opinion in oncology.

[18]  M. Falagas,et al.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[19]  E. Bow.  Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients , 2011, Current opinion in infectious diseases.

[20]  E. Gonzalez-Billalabeitia,et al.  Prognostic evaluation of febrile neutropenia in apparently stable adult cancer patients , 2011, British Journal of Cancer.

[21]  B. Rapoport.  Management of the cancer patient with infection and neutropenia. , 2011, Seminars in oncology.

[22]  P. Hsueh,et al.  Epidemiology of bloodstream infections in patients with haematological malignancies with and without neutropenia , 2009, Epidemiology and Infection.

[23]  D. Warren,et al.  Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  R. Feld.  Bloodstream infections in cancer patients with febrile neutropenia. , 2008, International journal of antimicrobial agents.

[25]  A. Hidrón,et al.  Antimicrobial-Resistant Pathogens Associated With Healthcare-Associated Infections: Annual Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006–2007 , 2008, Infection Control & Hospital Epidemiology.

[26]  G. Rossi,et al.  Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with haematological malignancies: results of a prospective study on 823 patients at a single institution. , 2008, The Journal of antimicrobial chemotherapy.

[27]  K. Rolston,et al.  Risk factors for infections with multidrug‐resistant Stenotrophomonas maltophilia in patients with cancer , 2007, Cancer.

[28]  G. Lyman,et al.  Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients , 2006, Cancer.

[29]  R. Foà,et al.  Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. , 2005, The New England journal of medicine.

[30]  V. Caggiano,et al.  Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy , 2005, Cancer.

[31]  C. Viscoli,et al.  Infections in patients with febrile neutropenia: epidemiology, microbiology, and risk stratification. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  Yee-Chun Chen,et al.  Trends and antimicrobial resistance of pathogens causing bloodstream infections among febrile neutropenic adults with hematological malignancy. , 2004, Journal of the Formosan Medical Association = Taiwan yi zhi.

[33]  G. Lyman,et al.  Chemotherapy‐induced neutropenia , 2004, Cancer.

[34]  F. Cainelli,et al.  Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment. , 2003, The Lancet. Oncology.

[35]  L. Elting,et al.  The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  L. Young,et al.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  Gary H Lyman,et al.  Management of chemotherapy-induced neutropenia: measuring quality, cost, and value. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.

[38]  K. Sepkowitz,et al.  Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[39]  Clinical,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : Approved standard , 2006 .

[40]  Clinical,et al.  Performance standards for antimicrobial disk susceptibility tests : approved standard , 2006 .

[41]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .